Rupesin E exhibits significant antifungal activity, particularly against pathogenic Candida species, making it a potential candidate for development as an antifungal agent. It has shown effectiveness in inhibiting biofilm formation, which is a key factor in persistent fungal infections, especially those associated with medical devices. Due to its ability to disrupt fungal cell membranes, Rupesin E is being studied for use in topical treatments for skin and mucosal infections. Additionally, its selective toxicity toward fungal cells over mammalian cells suggests a favorable safety profile for therapeutic applications. Research is ongoing to evaluate its efficacy in combination with existing antifungals to combat drug-resistant strains.